Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Recent data indicate that patients with vascular dementia (VaD) show a cholinergic deficit. Having obtained good results in a previous study comparing rivastigmine, an inhibitor of acetylcholinesterase (AChE) and butyrylcholine-sterase (BuChE), vs. aspirin, we aimed to compare the efficacy and tolerability of rivastigmine vs. aspirin plus nimodipine. Patients with a diagnosis of dementia and probable VaD received rivastigmine 3-6 mg/day (n = 32) or aspirin plus nimodipine (n = 32) in an open study for 16 months. Patients treated with rivastigmine showed superior benefits, compared with those receiving aspirin plus nimodipine, in attention, executive function, instrumental activities of daily living, and behavioural and psychotic disturbances. Side-effects in both groups were tolerable and there were no study withdrawals. The benefits observed with rivastigmine may reflect its inhibitory effects on AChE and BuChE, and the drug's affinity for frontal brain areas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J., Kertesz, A., Pratt, R. D., & the Donepezil 308 Study Group* (2003) · Neurology · doi:10.1212/01.wnl.0000078943.50032.fc · Cited by 392
Black, S., Román, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., Perdomo, C., Kumar, D., & Pratt, R. (2003) · Stroke · doi:10.1161/01.str.0000091396.95360.e1 · Cited by 386
Differentiation of vascular dementia from AD on neuropsychological tests
Looi, J. C. L., & Sachdev, P. S. (1999) · Neurology · doi:10.1212/wnl.53.4.670 · Cited by 382
Rivastigmine in subcortical vascular dementia
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00280-0 · Cited by 107
Self-citation
Cited by
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Parnetti, L., Mignini, F., Tomassoni, D., Traini, E., & Amenta, F. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.043 · Cited by 122
Traini, E., Bramanti, V., & Amenta, F. (2013) · Current Alzheimer Research · doi:10.2174/15672050113106660173 · Cited by 78
“On the other hand this trial, different from previous studies with choline alphoscerate [47] has used batteries of tests and time of observation comparable with studies assessing the activity of (acetyl) cholinesterase inhibitors [49-56].”
ResultRivastigmine for vascular cognitive impairment
Craig, D., & Birks, J. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004744.pub2 · Cited by 42
Metadata
- Authors
- Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., Griggio, S., Ukmar, M., & Bava, A.
- Venue
- International Journal of Clinical Practice
- Publisher
- Hindawi Limited
- Published
- 2004-04-29
- Volume
- 58
- Issue
- 4
- Pages
- 346-353
- ISSN
- 1368-5031 (ISSN-L)
- OpenAlex
- W2162252402
- Cited by
- 41
- References
- 4
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. https://app.cochat.ai/papers/10.1111/j.1368-5031.2004.00127.x
- The paper
- Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., Griggio, S., Ukmar, M., & Bava, A. (2004). Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. International Journal of Clinical Practice. https://doi.org/10.1111/j.1368-5031.2004.00127.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.